Our team has experience spanning the globe, including the Americas, Asia, Europe, India, South Africa, and Australia, bringing a strong global perspective to the clinical development, Biometrics, and Medical Writing services we offer. InClin has an established network of highly experienced project managers and field monitors throughout the United States, Europe, and Asia, in addition to world-class Biometrics and Medical Writing support. This extremely flexible team is committed to providing close personal attention and support to each project and is the driving force behind our success.
Arnold G. Wong (Cofounder and Chief Executive Officer) has hands-on experience in nonclinical research and extensive experience in clinical research. Before becoming CEO of InClin, Mr. Wong was the CFO of InClin. He held positions of an Associate Scientist at Cardima, Inc., COR Therapeutics, and Syntex Research. Previously, as InClin Senior Project Manager, Mr. Wong was responsible for management of clinical operations teams and liaison with Sponsor clients. Mr. Wong has a BS in physiology from the University of California at Davis.
Taylor T. Kilfoil (Cofounder and Chief International Officer) was the previous President and Chief Executive Officer of InClin. Mr. Kilfoil has 25+ years of pharmaceutical and biotech industry experience. Since cofounding InClin in 1998, Mr. Kilfoil has held a wide spectrum of senior level consultant positions at multiple pharmaceutical and biotechnology companies where he provided both clinical operations and project management support for their domestic and international clinical development programs. He started his career at Syntex Research conducting nonclinical pharmacology drug development research where he moved into the clinical research arena. Mr. Kilfoil has extensive experience in Phase 1 to 3 drug development. Mr. Kilfoil has a BS in psychobiology from Saint John’s University.
Brian Horger, PhD
Brian Horger, Ph.D (Vice President, Business Development and Chief Operations Officer) has broad and extensive experience in the pharmaceutical and drug development industry. Dr. Horger began his career as a Research Scientist at Yale University School of Medicine. Subsequently he held industry positions and led drug discovery efforts in Parkinson’s Disease at Genentech and smooth muscle disorders at Theravance. Over the last 10 years Dr. Horger has served as a Director of Business Development at MDS Pharma Services and Covance Early Clinical Services. Dr. Horger has a PhD in Neuroscience from Texas A&M University.
George F. Faurot (Senior Vice President, Clinical Operations) has hands-on preclinical research experience (7 years) and extensive experience in clinical research (17 years). Previously, as Senior Partner and Vice President, Clinical Operations at InClin, Mr. Faurot was responsible for the planning, implementation, and execution of Phase 1 to 3 clinical development programs for multiple pharmaceutical sponsors, 3 of which resulted in successful NDA approvals. Mr. Faurot has a BS in environmental toxicology from the University of California at Davis.
Marc R. Perry (Senior Vice President, Quality) is a member of the original management team that founded InClin and has served as a managing partner contributing to the successful growth of the company during the past 14 years. Mr. Perry has hands-on nonclinical research experience and broad global clinical operations experience derived from Global Project Management positions responsible for managing multiple global Phase 3 programs. The development programs Mr. Perry has helped manage have led to 2 successful NDA submissions and 2 market approvals. Mr. Perry studied biological sciences at the University of Montana and pharmacology at the University of California, Santa Barbara.
Gary Witherell, PhD
Gary Witherell, PhD (Vice President, Medical Communications) has extensive experience supervising medical writing teams and has written a large number and variety of scientific, clinical, and regulatory documents. In 2011, Dr. Witherell cofounded Pfluent. Prior to Pfluent, Dr. Witherell led medical writing groups at Cerexa and Chiron. In addition, Dr. Witherell gained hands-on experience in drug discovery, nonclinical research, clinical development, and medical affairs at RiboGene, Questcor, and Chiron. Dr. Witherell has a PhD in biochemistry from the University of Colorado and a BS in biochemistry from the University of Iowa. Dr. Witherell was a Postdoctoral Fellow at the State University of New York-Stony Brook.